Jill Bayliss

Jill Bayliss

Auto-generated profile, based on publicly available information

Jill Bayliss

Laboratory of Brain Tumor Metabolism and Epigenetics, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2017 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
PPPooja Panwalkar
Pooja Panwalkar
JCJonathan Clark
Jonathan Clark
Vijay RamaswamyVijay Ramaswamy
Vijay Ramaswamy
DHDebra Hawes
Debra Hawes
FYFusheng Yang
Fusheng Yang
SVSriram Venneti
Sriram Venneti

13 August 2020 in Cancer Cell
Verified
Journal Article
Closed access
CCChan Chung
Chan Chung
SSStefan R. Sweha
Stefan R. Sweha
DPDrew Pratt
Drew Pratt
BTBenita Tamrazi
Benita Tamrazi
PPPooja Panwalkar
Pooja Panwalkar
SVSriram Venneti
Sriram Venneti

23 November 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JBJill Bayliss
Jill Bayliss
PMPiali Mukherjee
Piali Mukherjee
CLChao Lu
Chao Lu
SJSiddhant U. Jain
Siddhant U. Jain
CCChan Chung
Chan Chung
SVSriram Venneti
Sriram Venneti
A subset of childhood posterior fossa ependymomas with poor prognosis is epigenetically similar to H3K27M gliomas.

1 December 2007 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JBJill Bayliss
Jill Bayliss
AHAmy Hilger
Amy Hilger
PVPrakash Vishnu
Prakash Vishnu
KDKathleen Diehl
Kathleen Diehl
DEDorraya El-Ashry
Dorraya El-Ashry
Purpose: In breast cancer, the presence of estrogen receptor α (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERα correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERα expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERα− breast cancer cell lines and tumors results in reexpression of ERα, and further, if reexpression of ERα in these ERα− tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERα− breast cancer cell lines, ERα− breast tumors, and tumor cell cultures obtained from ERα− tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase 1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin. Western blotting or reverse transcription-PCR for ERα was used to assess the reexpression of ERα in cells treated with U0126. Growth assays with WST-1 were done to assess restoration of antiestrogen sensitivity in these cells. Results: Inhibition of MAPK activity in ERα− breast cancer cell lines results in reexpression of ERα; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERα can now mediate an antiestrogen response in a subset of these ERα− breast cancer cell lines. Treatment of ERα− tumor specimens with MAPK inhibitors results in restoration of ERα mRNA, and similarly in epithelial cultures from ERα− tumors, MAPK inhibition restores both ERα protein and antiestrogen response. Conclusions: These data show both the possibility of restoring ERα expression and antiestrogen responses in ERα− breast cancer and suggest that there exist ERα− breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.

1 October 2014 in Acta Biomaterialia
Verified
Journal Article
Closed access
EBElizabeth J. Brisbois
Elizabeth J. Brisbois
JBJill Bayliss
Jill Bayliss
JWJianfeng Wu
Jianfeng Wu
TMTerry C. Major
Terry C. Major
CXChuanwu Xi
Chuanwu Xi
MMMark E. Meyerhoff
Mark E. Meyerhoff

6 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PPPooja Panwalkar
Pooja Panwalkar
BTBenita Tamrazi
Benita Tamrazi
DDDerek Dang
Derek Dang
CCChan Chung
Chan Chung
SSStefan Sweha
Stefan Sweha
SVSriram Venneti
Sriram Venneti
Childhood posterior fossa group A ependymomas demonstrate integrated metabolic and epigenetic pathways that can be disrupted by metformin.